Page 3 - Precigen News Today

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) SVP Jeffrey Thomas Perez sold 8,741 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $1.55, for a total value of $13,548.55. Following the completion of the sale, the senior vice president now owns 448,916 shares […]

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) Director Steven Frank purchased 400,000 shares of Precigen stock in a transaction on Monday, August 14th. The shares were purchased at an average cost of $1.72 per share, with a total value of $688,000.00. Following the transaction, the director now owns 882,358 shares in the company, valued at […]

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) insider Donald P. Lehr sold 10,821 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $1.20, for a total transaction of $12,985.20. Following the completion of the sale, the insider now directly owns 396,521 […]

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) SVP Jeffrey Thomas Perez sold 8,789 shares of Precigen stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $1.20, for a total value of $10,546.80. Following the sale, the senior vice president now directly owns 428,857 shares in the company, […]

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) SVP Jeffrey Thomas Perez sold 8,789 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $1.20, for a total transaction of $10,546.80. Following the completion of the sale, the senior vice president now owns 428,857 shares […]

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...

– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion...

By Chris Wack Precigen said Wednesday the U.S. Food and Drug Administration has cleared the Investigational New Drug application to begin a Phase 2 study of its first-in-class PRGN-2009... | May 31, 2023

JPMorgan Chase & Co. started coverage on shares of Precigen (NASDAQ:PGEN – Get Rating) in a report released on Tuesday morning, The Fly reports. The brokerage issued a neutral rating on the biotechnology company’s stock. PGEN has been the subject of a number of other research reports. HC Wainwright reaffirmed a buy rating and issued […]

JPMorgan Chase & Co. started coverage on shares of Precigen (NASDAQ:PGEN – Get Rating) in a research report sent to investors on Tuesday morning, The Fly reports. The brokerage issued a neutral rating on the biotechnology company’s stock. A number of other equities analysts also recently weighed in on the stock. StockNews.com started coverage on […]